; and cases that remain unclassified (NC) 1, 6 . A key feature of ABC-DLBCL is the activation of the NF-kB signalling pathway, as shown by the preferential expression of known NF-kB target genes and the dependence of ABC-DLBCL cell lines on NF-kB activity for proliferation and survival 2, 7 . A recent study reported that ,8% of ABC-DLBCL carry oncogenic mutations of CARD11 (ref. 3 ), a cytoplasmic scaffolding protein required for activation of NF-kB during antigen-dependent signalling 8 . However, the molecular mechanism underlying NF-kB activation in the remaining large fraction of cases remains unknown, leaving open the possibility that it may reflect a physiological status of the normal ABC-DLBCL counterpart.
To address this issue, we first characterized 168 DLBCL samples, representative of major subtypes, for the presence of active NF-kB complexes by using immunohistochemical assays detecting nuclear NFKB1 (also called p50; read-out for the classical pathway) and NFKB2 (p52; alternative pathway) 9, 10 (Fig. 1a) . Nuclear localization of NF-kB was observed in the tumour cells of 61% of ABC-DLBCL and a smaller fraction (30%) of GCB-DLBCL, as well as in 3 out of 9 unclassified and 36 out of 73 not profiled DLBCL (Fig. 1b) . Both classical and alternative NF-kB pathways were found to be involved, occasionally within the same sample (one-third of the positive cases), and consistent with the established role of specific signals (for example, CD40-CD40L) in the activation of both pathways 11, 12 . Engagement of the alternative NF-kB pathway was also documented by detection of p52, the active product of p100 processing, in western blot assays (Fig. 1c) . Gene set enrichment analysis (GSEA) of transcriptionally profiled cases confirmed that the gene expression signature of ABC-DLBCL is significantly enriched in NF-kB target genes (Supplementary Table 1 ) with respect to both normal GC centroblasts, used as negative control 13 (P , 0.005; not shown), and GCB-DLBCL (P 5 0.03; Fig. 1d ). Moreover, all immunohistochemistry-positive samples displayed a transcriptional signature of NF-kB pathway activity. The fraction of cases presenting high NF-kB transcriptional activity by GSEA was higher than that defined by immunohistochemistry (.95% ABC-DLBCL and ,47% GCB-DLBCL; Fig. 1e, f) . This difference probably reflects the higher sensitivity of gene-expression-profile-based approaches, but also their inability to discriminate signals deriving from infiltrating reactive cells. Thus, immunohistochemistry may provide a rapid and specific, although relatively less sensitive, approach for the identification of constitutively active NF-kB on routine diagnostic material. Both methods revealed that NF-kB signalling is not limited to ABC-DLBCL, but may also be present in a smaller subset of GCB-DLBCL.
To investigate whether constitutive NF-kB activation in ABC-DLBCL represents a primary pathogenetic event or reflects the intrinsic program of the tumour cell of origin, we screened for mutations the complete coding sequence of 31 NF-kB-pathway genes in 14 samples (Supplementary Table 2) . Genes found mutated after filtering for known polymorphisms and synonymous mutations were further analysed in a validation panel composed of 87 DLBCL (23 ABC, 44 GCB and 20 unclassified/non-GC; Supplementary Fig. 1 ).
This strategy identified a total of 48 sequence changes distributed in 6 different genes, including the NF-kB negative regulator A20 (TNFAIP3) [14] [15] [16] 20 (Table 1 and Supplementary Table 3 ). Mutations were preferentially associated with the ABC-DLBCL phenotype, where 51.3% of the samples analysed showed alterations in one or more gene, compared with 22.7% GCB-DLBCL (Table 1 and  Supplementary Table 4 ). In addition, 7 out of 20 (35%) non-GC DLBCLs were found to be mutated. Analysis of paired normal DNA, available from 8 samples, indicated the somatic origin of these events in at least one sample/gene.
The most commonly affected gene was A20, which codes for a dual function ubiquitin-modifying enzyme belonging to the ovarian tumour (OTU) domain-containing family of deubiquitinating enzymes and required for termination of NF-kB responses in the classical NF-kB pathway [14] [15] [16] . Notably, the A20 locus is positioned on chromosomal band 6q23.3, a region frequently deleted in aggressive B-cell lymphomas, and suggested to contain a tumour suppressor 21, 22 .
We therefore examined this gene in 68 additional DLBCL biopsies, immunohistohemically classified as GC and non-GC based on the Hans algorithm, with minor modifications (see Methods) 23 . Combined, the two screenings led to the identification of 26 mutational events, distributed in 22 cases and almost exclusively segregating with an ABC/non-GC phenotype (9 out of 37 ABC-DLBCL and 10 out of 51 non-GC/NC-DLBCL, versus 2 out of 72 GCB-DLBCL; Fig. 2a ). Sequence changes included nonsense mutations introducing premature termination codons (n 5 12); frameshift deletions/insertions (n 5 7 and 5, respectively); and nucleotide substitutions at consensus splice donor sites (n 5 2), which were documented by cDNA amplification and sequencing to generate aberrant transcripts that retain intronic sequences and have lost their coding potential ( Fig. 2b and Supplementary Table 5 ). The common consequence of these mutations is the production of severely truncated A20 polypeptides that lack functionally relevant domains ( Supplementary Fig. 2 ) and are either unstable or functionally impaired, as experimentally demonstrated in transient transfection/NF-kB reporter gene assays ( Supplementary Fig. 3 ) 14, 16 . In four samples, each displaying two mutational events, sequencing analysis of A20 transcripts after cDNA amplification and cloning demonstrated that the mutations were located on separate alleles, leading to biallelic gene inactivation. Moreover, fluorescence in situ hybridization (FISH) analysis using specific probes and/or direct sequencing revealed deletion of the second allele in 12 out of 14 mutated cases with available material (Fig. 2c, d and Supplementary Table 5 ). Homozygous A20 deletions were found in seven additional cases, one of which harboured a focal deletion (,420 kilobases (kb)) encompassing A20 and OLIG3, a gene not expressed in B cells ( Supplementary Fig. 4 and Supplementary Table 6 ), providing strong evidence for A20 being the target of the lesion. In all samples, loss of the signal accounted for $90% of the tumour cell population, consistent with a clonally represented event (Supplementary Table 7) . Thus, 32% of ABC-DLBCL and ,34% of non-GC/NC-DLBCL have lost both copies of the A20 gene due to the presence of inactivating mutations and/or deletions (Fig. 2e) . Notably, monoallelic deletions were also observed in 23% of ABC-DLBCL and ,22% of non-GC-DLBCL. Because expression of the wild-type allele was still detected in the three cell lines investigated, these data may suggest haploinsufficiency or the involvement of a second gene in the context of larger 6q chromosomal deletions, frequently observed in aggressive lymphomas 21 . Collectively, these findings indicate that A20 is frequently inactivated in DLBCL by a two-hit mechanism typical of tumour suppressor genes.
To test directly the role of A20 in cell transformation, we used lentiviral expression vectors and reintroduced A20 in two cell lines (SUDHL2 and RC-K8) carrying biallelic A20 gene inactivation. As shown in Fig. 3a-c, A20 reconstitution induced apoptosis and cell growth arrest in the A20-null cell lines, but not in two control lines carrying an intact A20 locus and lacking constitutive NF-kB activity. Consistently, fluorescence-activated cell sorting (FACS) analysis of green fluorescent protein (GFP) expression documented the progressive disappearance of the A20-positive population (identified by GFP) in SUDHL2 and RC-K8, as opposed to SUDHL4 and SUDHL7 or to empty-vector-transduced cells, where .90% of the population was GFP 1 8 days after sorting (Fig. 3d) . Notably, most A20-reconstituted cells showed complete cytoplasmic relocation of p50 by immunofluorescence staining (Fig. 3e) , indicating an A20-dependent block in NF-kB signalling and consistent with its well established role in the termination of NF-kB responses in vitro and in vivo [14] [15] [16] . Together, these findings strongly suggest a tumour suppressor role for A20, the loss of which may contribute to DLBCL pathogenesis by causing supra-physiological activation of NF-kB which, in turn, has oncogenic properties via inhibiting apoptosis and promoting cell proliferation 24 . Less commonly, missense mutations were found in positive regulators of the NF-kB pathway, namely the scaffolding proteins CARD11 (11%), TRAF2 (3%) and TRAF5 (5%), which mediate NF-kB activation via oligomerization and activation of the IKK kinase; the MAP3K7 serine-threonine kinase (5%), which directly LETTERS phosphorylates IKK 20, 25 ; and the cell-surface receptor TNFRSF11A (8.1%), involved in classical NF-kB responses (Table 1 and Supplementary Table 8 ). Notably, single nucleotide polymorphism (SNP)-array data showed amplification of the regions harbouring these genes in 41 cases, suggesting their possible dominant role in activating NF-kB (not shown). To investigate the functional significance of these mutations, we examined their ability to activate a luciferase reporter vector driven by two NF-kB-responsive elements in transient transfection assays. In agreement with a recent study 3 , CARD11 mutations potentiate its NF-kB transactivation activity, in the absence of further stimuli ( Supplementary Fig. 6a, b) . Significantly enhanced NF-kB activity was also observed on transfection of the ABC-DLBCL-derived TRAF2(P186R) mutant ( Supplementary  Fig. 6c ). When expressed in the DLBCL cell line SUDHL6, which lacks constitutive NF-kB activity, this mutant was sufficient to induce nuclear p50 translocation in most cells, indicating its ability to stimulate this pathway in vivo (Supplementary Fig. 6d ). Conversely, no significant differences were associated with four GCB-derived TRAF2 mutant alleles and with the mutant MAP3K7 allele (not shown). Because these mutations were mostly observed in cell lines, their somatic origin could not be verified, leaving open the possibility that they represent polymorphisms that have not been reported previously. Alternatively, these data may suggest a more subtle effect of the mutations, not detectable by the experimental approach used. Although further studies will be required to dissect the significance of these alterations in vivo, our data show that at least 15 out of 37 (40.5%) ABC-DLBCL (those with A20, CARD11 and TRAF2 alterations) display mutations of proven functional significance in activating NF-kB.
The identification of multiple genetic alterations converging on the same pathway in a sizable fraction of ABC-DLBCL provides a genetic explanation for the presence of constitutive NF-kB activity in this tumour type, indicating a role for this signalling pathway as a primary pathogenetic event in lymphomagenesis. The most prominent player in this scenario is the known NF-kB negative regulator A20. Notably, structural alterations affecting this gene are also found in Hodgkin's lymphoma, PMBL and marginal zone lymphoma 26, 27, 28 . These findings, together with the evidence of its functional role in modulating NF-kB [14] [15] [16] , identify A20 as a relevant tumour suppressor gene, the inactivation of which may contribute to the pathogenesis of several lymphoma subtypes. Because A20 is itself a target of NF-kB and needs to be induced in order to exert its negative feedback effect, additional upstream events are probably required by the tumour cells to activate this signalling cascade and promote selective pressure for A20 inactivation, including engagement of the B-cell receptor by the antigen, CD40-CD40L signalling and BAFF-BAFFR interaction. However, the observation that, in some cases, multiple genes are simultaneously altered within this signalling pathway, as a combination of positive and negative regulators (for example, A20 and TNFRSF11A or MAP3K7), suggests that additional upstream genetic lesions may complement the loss of A20.
Constitutive NF-kB activation may promote malignant transformation by providing anti-apoptotic and pro-proliferative signals. Notably, these lesions occur in the same cases displaying structural alterations of BCL6 and BLIMP1 29, 30 , which may contribute to lymphomagenesis by suppressing genotoxic responses (BCL6) 31 and/or preventing terminal B-cell differentiation (BCL6, BLIMP1) 30 . As such, these findings provide the rationale and the assays for the identification of DLBCL patients potentially benefiting from targeted anti-NF-kB therapeutic approaches.
METHODS SUMMARY
Characterization of NF-kB activity. The presence of active NF-kB complexes in DLBCL cell lines and primary biopsies was analysed by immunohistochemistry and immunofluorescence analysis of paraffin-embedded tissue sections and cytospin preparations using anti-p105/p50 and anti-p100/p52 antibodies, and by GSEA of NF-kB target genes on Affymetrix U133Plus_2 gene expression profile data.
Mutation analysis. The complete coding sequences and exon/intron junctions of 31 NF-kB genes were analysed by PCR amplification and direct sequencing of genomic DNA as described 30 . Mutations were confirmed by sequencing of both strands on independent PCR products, whereas previously reported polymorphisms, changes present in matched normal DNA and silent mutations were filtered from the analysis. FISH analysis. FISH analysis was performed on tissue microarrays using two specific BAC probes spanning the A20 gene and a centromeric probe for chromosome 6 (ref. 30) . Lentiviral transduction of A20 expression constructs. For the reconstitution assay, DLBCL cell lines were transduced with lentiviral vectors expressing GFP alone (pWPI) or wild-type human A20 linked to IRES-GFP (pWPI-HA-A20), and analysed for effects on survival, cell growth and NF-kB activity. Productively transduced (GFP 1 ) cells were purified by cell sorting before use in proliferation assays and immunofluorescence staining of nuclear p50.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
